Analysis on disease burden and epidemiological trends of HIV/AIDS co-infection with drug-resistant tuberculosis in China on the global perspective

CHEN Chen; FU Han; LIU Yulong; CHEN Shiqi; WANG Fei; LIU Ruru; ZHANG Yiwei; WANG Xin

doi:10.16462/j.cnki.zhjbkz.2025.08.013

Volume 29 Issue 8

Aug. 2025

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2025 > 29(8): 949-955

CHEN Chen, FU Han, LIU Yulong, CHEN Shiqi, WANG Fei, LIU Ruru, ZHANG Yiwei, WANG Xin. Analysis on disease burden and epidemiological trends of HIV/AIDS co-infection with drug-resistant tuberculosis in China on the global perspective[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(8): 949-955. doi: 10.16462/j.cnki.zhjbkz.2025.08.013

Citation:

CHEN Chen, FU Han, LIU Yulong, CHEN Shiqi, WANG Fei, LIU Ruru, ZHANG Yiwei, WANG Xin. Analysis on disease burden and epidemiological trends of HIV/AIDS co-infection with drug-resistant tuberculosis in China on the global perspective[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(8): 949-955. doi: 10.16462/j.cnki.zhjbkz.2025.08.013

Citation:

CHEN Chen, FU Han, LIU Yulong, CHEN Shiqi, WANG Fei, LIU Ruru, ZHANG Yiwei, WANG Xin. Analysis on disease burden and epidemiological trends of HIV/AIDS co-infection with drug-resistant tuberculosis in China on the global perspective[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(8): 949-955. doi: 10.16462/j.cnki.zhjbkz.2025.08.013

PDF( 4981 KB)

Analysis on disease burden and epidemiological trends of HIV/AIDS co-infection with drug-resistant tuberculosis in China on the global perspective

doi: 10.16462/j.cnki.zhjbkz.2025.08.013

1.
Department of Disinfection and Infection Control, Xi'an Center for Disease Control and Prevention, Xi'an 710054, China
2.
Laboratory of Physical and Chemical Testing, Xi'an Center for Disease Control and Prevention, Xi'an 710054, China

More Information

Corresponding author: WANG Xin, E-mail: wangxin12675@163.com
Received Date: 2025-04-23
Rev Recd Date: 2025-06-12
Publish Date: 2025-08-10

Abstract

Abstract

Objective To analyze the disease burden and trends of human immunodeficiency virus (HIV)-induced acquired immune deficiency syndrome (AIDS) co-infection with drug-resistant tuberculosis-including multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB)-in China from 1995 to 2021, and to provide scientific evidence for optimizing prevention and control strategies. Methods Data on age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) were extracted from the Global Burden of Disease (GBD) 2021 database. Joinpoint regression models were used to calculate annual percentage change (APC) and average annual percent change (AAPC) for both incidence and mortality rates and to identify turning points. Results From 1995 to 2021, the age-standardized incidence rate (ASIR) and mortality rate (ASMR) of HIV/AIDS-associated multidrug-resistant tuberculosis (MDR-TB) in China decreased from 1.40 per 10 000 and 0.33 per 10 000 to 0.61 per 10 000 and 0.16 per 10 000, respectively, but increased again after 2015. Although baseline values were low, both ASIR and ASMR of HIV/AIDS-associated extensively drug-resistant tuberculosis (XDR-TB) exhibited statistically significant upward trends [AAPC: 5.83% (t=15.12, P < 0.05) and 6.38% (t=9.96, P < 0.05), respectively]. Sex analysis revealed that female demonstrated greater declines in ASIR and ASMR for both HIV/AIDS-MDR-TB and HIV/AIDS-XDR-TB than male. Significant increases in incidence and mortality of HIV/AIDS-MDR-TB were observed in the 5- < 15 year group. All age groups showed increasing incidence and mortality of HIV/AIDS-XDR-TB during the study period. Conclusions China needs to establish a precise prevention and control system for HIV/AIDS drug-resistant tuberculosis, with a focus on enhancing screening among male and adolescent populations, promoting rapid diagnostic techniques, and standardizing the management of anti-tuberculosis drugs.
- Human immunodeficiency virus/acquired immune deficiency syndrome,
- Drug-resist tuberculosis,
- Disease burden

FullText(HTML)

References(14)

References

[1]	Lan QW, Chen HK, Huang ZM, et al. Global, regional, and national time trends in incidence for tuberculosis, 1990-2019: an age-period-cohort analysis for the Global Burden of Disease 2019 study[J]. Heart Lung, 2024, 65: 19-30. DOI: 10.1016/j.hrtlng.2024.01.009.
[2]	王歆尧, 姜美丽, 庞元捷, 等. 中国结核病疾病负担现状[J]. 中华流行病学杂志, 2024, 45(6): 857-864. DOI: 10.3760/cma.j.cn112338-20240311-00111. Wang XY, Jiang ML, Pang YJ, et al. Current status of tuberculosis burden in China[J]. Chin J Epidemiol, 2024, 45(6): 857-864. DOI: 10.3760/cma.j.cn112338-20240311-00111.
[3]	Wu YX, Zhang YN, Wang YY, et al. Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: a systematic review and Meta-analysis[J]. Pharmacol Res, 2022, 182: 106336. DOI: 10.1016/j.phrs.2022.106336.
[4]	Song YL, Jin Q, Qiu JH, et al. A systematic review and Meta-analysis on the correlation between HIV infection and multidrug-resistance tuberculosis[J]. Heliyon, 2023, 9(11): e21956. DOI: 10.1016/j.heliyon.2023.e21956.
[5]	胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读[J]. 结核与肺部疾病杂志, 2024, 5(6): 500-504. DOI: 10.19983/j.issn.2096-8493.2024164. Hu XY, Gao JT. Interpretation of WHO global tuberculosis report 2024[J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 500-504. DOI: 10.19983/j.issn.2096-8493.2024164.
[6]	陈诚, 刘炯雅, 孙郑, 等. 结核病防控进展[J]. 中华疾病控制杂志, 2025, 29(4): 373-377. DOI: 10.16462/j.cnki.zhjbkz.2025.04.001. Chen C, Liu JY, Sun Z, et al. Progress in tuberculosis prevention and control[J]. Chin J Dis Control Prev, 2025, 29(4): 373-377. DOI: 10.16462/j.cnki.zhjbkz.2025.04.001.
[7]	Sun R, Wang L, Xia HF. Disease burden of tuberculosis in China from 1990 to 2021 and its prediction to 2036[J]. Front Public Health, 2025, 12: 1506266. DOI: 10.3389/fpubh.2024.1506266.
[8]	郑锡文. 我国艾滋病流行病学监测现状[J]. 中华医学信息导报, 2001, 16(19): 7-9. Zheng XW. Situation of China HIV/AIDS epidemiological surveillance[J]. Chin Med News, 2001, 16(19): 7-9.
[9]	蒋博峰, 马晨晨, 陈阳贵, 等. 抗结核药物不良反应发生率及其影响因素分析[J]. 中华疾病控制杂志, 2017, 21(2): 160-163. DOI: 10.16462/j.cnki.zhjbkz.2017.02.013. Jiang BF, Ma CC, Chen YG, et al. Analysis on the incidence of adverse reaction and risk factors caused by anti-tuberculosis drugs[J]. Chin J Dis Control Prev, 2017, 21(2): 160-163. DOI: 10.16462/j.cnki.zhjbkz.2017.02.013.
[10]	肖芮. 结核病控制中现代结核病控制策略应用的效果研究[J]. 中国全科医学, 2011, 14(26): 2995-2996. Xiao R. Effect of modern tuberculosis control strategy application in tuberculosis control[J]. Chinese J General Practice, 2011, 14(26): 2995-2996.
[11]	中华人民共和国卫生部. 卫生部办公厅关于印发《全国结核菌/艾滋病病毒双重感染防治工作实施方案(试行)》的通知[EB/OL]. (2010-08-03)[2025-04-17]. http://www.gov.cn/zwgk/2010-08/03/content_1670021.htm.
[12]	Liu EY, Wang Q, Zhang GQ, et al. Tuberculosis/HIV coinfection and treatment trends-China, 2015-2019[J]. China CDC Wkly, 2020, 2(48): 924-928. DOI: 10.46234/ccdcw2020.252.
[13]	Li XZ, Deng YF, Lin L, et al. HIV infection among TB and non-TB patients in China, 2009-2012[J]. Journal of Infection, 2014, 68(4): 399-400. DOI: 10.1016/j.jinf.2013.12.015.
[14]	Masini EO, Mansour O, Speer CE, et al. Using survival analysis to identify risk factors for treatment interruption among new and retreatment tuberculosis patients in Kenya[J]. PLoS One, 2016, 11(10): e0164172. DOI: 10.1371/journal.pone.0164172.